A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to help answer the following research questions, and not
to provide treatment for any condition:
- To evaluate how much of the study drug (LY2189265) is in the blood of participants with
varying degrees of liver impairment compared to those with normal liver function.
- To assess the safety of LY2189265 and any side effects that might be associated with it.